Released Nov 8, 2022, before the open
10-Q filed Nov 8, 2022, 39 days after period end · 0001628280-22-028930
Q3 2022 · 10-Q
Revenue$6.63M$6.63M +16,080.5% vs Q3 2021+47.8% vs Q2 2022
Net Income-$25.77M-$25.77M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.62-$0.62 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$28,259,000N/M
Operating Cash Flowderived-$19,986,000N/M
Free Cash Flowderived-$20,316,000N/M
Margins · derived
Operating margin-426.0%+63625.2 pt vs Q3 2021
Net margin-388.4%+63221.3 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $6.63M | $41.00K | $179.00K | — |
| Net Income | -$25.77M | -$26.08M | -$18.37M | -$13.09M |
| EPS Diluted | -$0.62 | -$0.71 | -$3.12 | -$3.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR